A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

NCT04784897 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Brilacidin
DRUG: Placebo
DRUG: Standard of Care (SoC)

Sponsor

Innovation Pharmaceuticals, Inc.